Dataset Information

Identifying the research, advocacy, policy and implementation needs for the prevention and management of respiratory syncytial virus lower respiratory tract infection in low- and middle-income countries.

ABSTRACT:

Introduction

The high burden of respiratory syncytial virus (RSV) infection in young children disproportionately occurs in low- and middle-income countries (LMICs). The PROUD (Preventing RespiratOry syncytial virUs in unDerdeveloped countries) Taskforce of 24 RSV worldwide experts assessed key needs for RSV prevention in LMICs, including vaccine and newer preventive measures.

Methods

A global, survey-based study was undertaken in 2021. An online questionnaire was developed following three meetings of the Taskforce panellists wherein factors related to RSV infection, its prevention and management were identified using iterative questioning. Each factor was scored, by non-panellists interested in RSV, on a scale of zero (very-low-relevance) to 100 (very-high-relevance) within two scenarios: (1) Current and (2) Future expectations for RSV management.

Results

Ninety questionnaires were completed: 70 by respondents (71.4% physicians; 27.1% researchers/scientists) from 16 LMICs and 20 from nine high-income (HI) countries (90.0% physicians; 5.0% researchers/scientists), as a reference group. Within LMICs, RSV awareness was perceived to be low, and management was not prioritised. Of the 100 factors scored, those related to improved diagnosis particularly access to affordable point-of-care diagnostics, disease burden data generation, clinical and general education, prompt access to new interventions, and engagement with policymakers/payers were identified of paramount importance. There was a strong need for clinical education and local data generation in the lowest economies, whereas upper-middle income countries were more closely aligned with HI countries in terms of current RSV service provision.

Conclusion

Seven key actions for improving RSV prevention and management in LMICs are proposed.

SUBMITTER: Carbonell-Estrany X

PROVIDER: S-EPMC9682277 | biostudies-literature | 2022

REPOSITORIES: biostudies-literature

ACCESS DATA

Publications

Identifying the research, advocacy, policy and implementation needs for the prevention and management of respiratory syncytial virus lower respiratory tract infection in low- and middle-income countries.

Carbonell-Estrany Xavier X Simões Eric A F EAF Bont Louis J LJ Gentile Angela A Homaira Nusrat N Scotta Marcelo Comerlato MC Stein Renato T RT Torres Juan P JP Sheikh Jarju J Broor Shobha S Khuri-Bulos Najwa N Nokes D James DJ Munywoki Patrick K PK Bassat Quique Q Sharma Arun K AK Basnet Sudha S Garba Maria M De Jesus-Cornejo Joanne J Lupisan Socorro P SP Nunes Marta C MC Divarathna Maduja M Fullarton John R JR Rodgers-Gray Barry S BS Keary Ian I Reñosa Mark Donald C MDC Verwey Charl C Moore David P DP Noordeen Faseeha F Kabra Sushil S do Vale Marynéa Silva MS Paternina-De La Ossa Rolando R Mariño Cristina C Figueras-Aloy Josep J Krilov Leonard L Berezin Eitan E Zar Heather J HJ Paudel Krishna K Safadi Marco Aurelio Palazzi MAP Dbaibo Ghassan G Jroundi Imane I Jha Runa R Rafeek Rukshan A M RAM Pinheiro Rossiclei de Souza RS Bracht Marianne M Muthugala Rohitha R Lanari Marcello M Martinón-Torres Federico F Mitchell Ian I Irimu Grace G Pandey Apsara A Krishnan Anand A Mejias Asuncion A da Costa Marcela Santos Corrêa MSC Shrestha Shrijana S Pernica Jeffrey M JM de Carvalho Felipe Cotrim FC Jalango Rose E RE Ibrahim Hafsat H Ewa Atana A Ensinck Gabriela G Ulloa-Gutierrez Rolando R Miralha Alexandre Lopes AL Lucion Maria Florencia MF Hassan Md Zakiul MZ Akhtar Zubair Z Aleem Mohammad Abdul MA Chowdhury Fahmida F Rojo Pablo P Sande Charles C Musau Abednego A Zaman Khalequ K Helena Luiza L Arlant Falleiros F Ghimire Prakash P Price April A Subedi Kalpana Upadhyay KU Brenes-Chacon Helena H Goswami Doli Rani DR Rahman Mohammed Ziaur MZ Hossain Mohammad Enayet ME Chisti Mohammod Jobayer MJ Vain Nestor E NE Lim Audrey A Chiu Aaron A Papenburg Jesse J Juarez Maria Del Valle MDV Senaratne Thamarasi T Arunasalam Shiyamalee S Strand Tor A TA Ayuk Adaeze A Ogunrinde Olufemi O Tavares Lohanna Valeska de Sousa LVS Garba Comfort C Garba Bilkisu I BI Dawa Jeanette J Gordon Michelle M Osoro Eric E Agoti Charles N CN Nyawanda Bryan B Ngama Mwanajuma M Tabu Collins C Mathew Joseph L JL Cornacchia Andrew A Rai Ganesh Kumar GK Jain Amita A Giongo Mateus Sfoggia MS Paes Bosco A BA

Frontiers in pediatrics 20221109

<h4>Introduction</h4>The high burden of respiratory syncytial virus (RSV) infection in young children disproportionately occurs in low- and middle-income countries (LMICs). The PROUD (Preventing RespiratOry syncytial virUs in unDerdeveloped countries) Taskforce of 24 RSV worldwide experts assessed key needs for RSV prevention in LMICs, including vaccine and newer preventive measures.<h4>Methods</h4>A global, survey-based study was undertaken in 2021. An online questionnaire was developed followi ...[more]

PMID: 36440349

Similar Datasets

Project description:ImportanceClinical trials have demonstrated high vaccine efficacy (VE) against lower respiratory tract disease (LRTD) but enrolled a smaller proportion of persons aged 75 years or older and those with comorbidities than seen in highest-risk populations in clinical practice settings. Additionally, VE against respiratory syncytial virus (RSV)-related hospitalizations and emergency department (ED) visits is not yet fully described.ObjectiveTo estimate Respiratory Syncytial Virus Prefusion F (RSVpreF) effectiveness in older adults.Design, setting, and participantsThis was a retrospective case-control study with a test negative design. Cases were adults aged 60 years or older with hospitalizations or ED visits at Kaiser Permanente of Southern California for LRTD from November 24, 2023, to April 9, 2024, who had respiratory swabs collected and tested for RSV. Two control definitions were prespecified: (1) strict controls included RSV-negative LRTD events that were negative for human metapneumovirus, SARS-CoV-2, and influenza, and positive for a nonvaccine preventable cause (primary) and (2) broad controls included all RSV-negative LRTD events (sensitivity analysis). Enhanced specimen collection was conducted to salvage clinical respiratory swabs not tested for RSV during routine care. Data were analyzed from May to September 2024.ExposureRSVpreF vaccine receipt during the first RSV season after licensure and 21 or more days before LRTD event.Main outcomes and measuresEstimated VE against first episode of RSV-related LRTD hospitalization or ED visit.ResultsA total of 7047 LRTD-related hospitalizations or ED encounters with RSV testing results were included. The mean (SD) age was 76.8 (9.6) years; 3819 (54.2%) were female; 839 (11.9%) were non-Hispanic Asian or Pacific Islander, 2323 (33.0%) were Hispanic, 1197 (17.0%) were non-Hispanic Black, and 2602 (36.9%) were non-Hispanic White; 998 (14.2%) were immunocompromised; and 6573 (93.3%) had 1 or more Charlson comorbidity. Using strict controls, estimated adjusted VE was 91% (95% CI, 59%-98%). Using broad controls, estimated adjusted VE was 90% (95% CI, 59%-97%).Conclusions and relevanceIn a high-risk, general population, RSVpreF vaccination conferred protection against RSV-related LRTD in the hospital and ED settings among US adults aged 60 years or older, the majority of whom were aged 75 years or older and had comorbidities. These data support use of this vaccine in older adults.

Dataset Information

Identifying the research, advocacy, policy and implementation needs for the prevention and management of respiratory syncytial virus lower respiratory tract infection in low- and middle-income countries.

Introduction

Methods

Results

Conclusion

Publications

Identifying the research, advocacy, policy and implementation needs for the prevention and management of respiratory syncytial virus lower respiratory tract infection in low- and middle-income countries.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets